BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 25585823)

  • 1. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.
    Shen XH; Liang SS; Chen HM; Le WB; Jiang S; Zeng CH; Zhou ML; Zhang HT; Liu ZH
    J Nephrol; 2015 Aug; 28(4):441-9. PubMed ID: 25585823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
    Zhang X; Shi S; Ouyang Y; Yang M; Shi M; Pan X; Lv J; Wang Z; Ren H; Shen P; Wang W; Zhang H; Xie J; Chen N
    J Transl Med; 2018 May; 16(1):115. PubMed ID: 29724226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.
    Chakera A; MacEwen C; Bellur SS; Chompuk LO; Lunn D; Roberts ISD
    J Nephrol; 2016 Jun; 29(3):367-375. PubMed ID: 26318019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crescentic IgA nephropathy in children.
    Shima Y; Nakanishi K; Hama T; Mukaiyama H; Sato M; Tanaka Y; Tanaka R; Kaito H; Nozu K; Sako M; Iijima K; Yoshikawa N
    Pediatr Nephrol; 2020 Jun; 35(6):1005-1014. PubMed ID: 31993782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and histopathologic profile of patients with primary IgA nephropathy seen in a tertiary hospital in India.
    Bagchi S; Singh G; Yadav R; Kalaivani M; Mahajan S; Bhowmik D; Dinda A; Agarwal SK
    Ren Fail; 2016; 38(3):431-6. PubMed ID: 26837482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
    Hou JH; Le WB; Chen N; Wang WM; Liu ZS; Liu D; Chen JH; Tian J; Fu P; Hu ZX; Zeng CH; Liang SS; Zhou ML; Zhang HT; Liu ZH
    Am J Kidney Dis; 2017 Jun; 69(6):788-795. PubMed ID: 28215945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.
    Trimarchi H; Barratt J; Cattran DC; Cook HT; Coppo R; Haas M; Liu ZH; Roberts IS; Yuzawa Y; Zhang H; Feehally J; ;
    Kidney Int; 2017 May; 91(5):1014-1021. PubMed ID: 28341274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.
    Wu H; Xia Z; Gao C; Zhang P; Yang X; Wang R; Wang M; Peng Y
    BMC Nephrol; 2020 Jul; 21(1):247. PubMed ID: 32611399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy.
    Bazzi C; Rizza V; Casellato D; Stivali G; Rachele G; Napodano P; Olivieri G; Gallieni M; D'Amico G
    J Nephrol; 2012; 25(5):810-8. PubMed ID: 22252844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.
    Xu K; Zhang L; Ding J; Wang S; Su B; Xiao H; Wang F; Zhong X; Li Y
    J Nephrol; 2018 Apr; 31(2):279-286. PubMed ID: 29185209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid therapy in children with IgA nephropathy.
    Cambier A; Boyer O; Deschenes G; Gleeson J; Couderc A; Hogan J; Robert T
    Pediatr Nephrol; 2020 Mar; 35(3):359-366. PubMed ID: 30778826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.
    Coppo R; Lofaro D; Camilla RR; Bellur S; Cattran D; Cook HT; Roberts IS; Peruzzi L; Amore A; Emma F; Fuiano L; Berg U; Topaloglu R; Bilginer Y; Gesualdo L; Polci R; Mizerska-Wasiak M; Caliskan Y; Lundberg S; Cancarini G; Geddes C; Wetzels J; Wiecek A; Durlik M; Cusinato S; Rollino C; Maggio M; Praga M; K Smerud H; Tesar V; Maixnerova D; Barratt J; Papalia T; Bonofiglio R; Mazzucco G; Giannakakis C; Soderberg M; Orhan D; Di Palma AM; Maldyk J; Ozluk Y; Sudelin B; Tardanico R; Kipgen D; Steenbergen E; Karkoszka H; Perkowska-Ptasinska A; Ferrario F; Gutierrez E; Honsova E
    Pediatr Nephrol; 2017 Jan; 32(1):139-150. PubMed ID: 27557557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical course of Immunoglobulin A nephropathy with crescents in a multi-ethnic Southeast Asian cohort.
    Lim CC; Baikunje S; Choo JCJ; Tan PH; Foo M; Woo KT
    Nephrology (Carlton); 2020 Sep; 25(9):708-713. PubMed ID: 32400945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin a nephropathy: Pathological markers of renal survival in paediatric patients.
    Fabiano RC; Pinheiro SV; de Almeida Araújo S; Simões E Silva AC
    Nephrology (Carlton); 2016 Dec; 21(12):995-1002. PubMed ID: 27414046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy.
    Alvarado AS; Andeen NK; Brodsky S; Hinton A; Nadasdy T; Alpers CE; Blosser C; Najafian B; Rovin BH
    Nephrol Dial Transplant; 2018 Jul; 33(7):1168-1175. PubMed ID: 28992348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.
    Coppo R; Troyanov S; Bellur S; Cattran D; Cook HT; Feehally J; Roberts IS; Morando L; Camilla R; Tesar V; Lunberg S; Gesualdo L; Emma F; Rollino C; Amore A; Praga M; Feriozzi S; Segoloni G; Pani A; Cancarini G; Durlik M; Moggia E; Mazzucco G; Giannakakis C; Honsova E; Sundelin BB; Di Palma AM; Ferrario F; Gutierrez E; Asunis AM; Barratt J; Tardanico R; Perkowska-Ptasinska A;
    Kidney Int; 2014 Oct; 86(4):828-36. PubMed ID: 24694989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive therapy in patients with IgA nephropathy.
    Peters HP; van den Brand JA; Berger SP; Wetzels JF
    Neth J Med; 2015 Jul; 73(6):284-9. PubMed ID: 26228193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of endocapillary hypercellularity lesions on the renal prognosis and response to immunosuppressive therapy in IgA nephropathy].
    Yang HY; Shi SF; Wang SX; Lyu JC; Zhang H
    Zhonghua Nei Ke Za Zhi; 2020 Nov; 59(11):894-897. PubMed ID: 33120494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
    Cruzado JM; Poveda R; Ibernón M; Díaz M; Fulladosa X; Carrera M; Torras J; Bestard O; Navarro I; Ballarín J; Romero R; Grinyó JM
    Nephrol Dial Transplant; 2011 Nov; 26(11):3596-602. PubMed ID: 21393611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.